Loading...
•
Dec 31, 2019
Zomedica Q4 2019 Earnings Report
Announced year end financial results, focusing on the development of TRUFORMA™ and preparations for commercialization.
Key Takeaways
Zomedica reported a net loss of $19.78 million for the year ended December 31, 2019, with no revenues recorded as the company is in the development stage. The loss was primarily due to research and development expenses, general and administrative expenses, and professional fees. The company is focused on completing the development and commencing commercialization of TRUFORMA™ by the end of 2020.
Net loss and comprehensive loss for the year ended December 31, 2019 was $19,784,054 or $0.19 per share.
Recorded no revenues in 2019 due to being in the development stage.
Research and development expenses were $10,345,291 for the year ended December 31, 2019.
Cash and cash equivalents were $510,586 as of December 31, 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...